Entering the Era of SARS-CoV-2 Antibody Testing: More Questions than Answers

A serologic test for antibodies against the SARS-CoV-2 nucleocapsid protein shows optimal specificity and sensitivity at day 14, but its prognostic role is unclear.

Researchers present data on the sensitivity and specificity of the Abbott SARS-CoV-2 immunoglobulin G (IgG) test, which detects IgG antibodies against the SARS-CoV-2 nucleocapsid protein.

When the SARS-CoV-2 assay was used on 1020 deidentified serum specimens from 1010 different individuals submitted in 2018 and 2019 for serologic testing of other viral infections, specificity was 99.9%. When the assay was used on 689 samples obtained from 125 patients with PCR-confirmed SARS-CoV-2 infection in March and April 2020, sensitivity was 53.1% at 7 days after the estimated day of symptom onset, 82.4% at 10 days, 96.9% at 14 days, and 100% at 17 days; sensitivity was 88.7% at 7 days after the date of PCR positivity, 97.2% at 10 days, 100% at 14 day…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Entering the Era of SARS-CoV-2 Antibody Testing: More Questions than Answers

Topics

Reviewing Author